Oragenics, Inc.·Healthcare

Oragenics, Inc. (NYSEAMERICAN:OGEN - Get Free Report) was the recipient of a significant increase in short interest during the month of March. As of March 13th, there was short interest totaling 792,779 shares, an increase of 39.0% from the February 26th total of 570,220 shares. Based on an average daily trading volume, of 442,572 shares,

SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2025, which was filed on March 16, 2026 with the Securities and Exchange Commission, the audited consolidated financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company's ability to continue as a going concern. See further discussion in footnote 1 to the Company's consolidated financial statements included in the Company's Annual Report on Form 10-K. This announcement is made pursuant to NYSE American LLC Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph. This announcement does not represent any change or amendment to the Company's financial statements or to its Annual Report on Form 10-K for the year ended December 31, 2025.

FIRST SITE INITIATION VISIT COMPLETED IN AUSTRALIA SARASOTA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced it has completed the first site initiation visit (SIV) for its Phase IIa clinical trial of ONP-002 in Australia.

SARASOTA, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that it is exploring discussions with third parties regarding the potential acquisition of additional assets in the central nervous system (CNS) space, with a specific focus on brain health and brain recovery indications that demonstrate strategic synergies with the Company's lead candidate ONP-002 and its proprietary intranasal drug delivery platform.

All required regulatory approvals secured for trial site onboarding and patient enrollment at three Australian sites Potential first and only pharmacological treatment for the most prominent neurological condition without an FDA-approved therapeutic

Shares of Oragenics, Inc. (NYSEAMERICAN:OGEN - Get Free Report) fell 0.3% during mid-day trading on Tuesday. The company traded as low as $0.7839 and last traded at $0.8295. 74,417 shares traded hands during mid-day trading, a decline of 82% from the average session volume of 421,599 shares. The stock had previously closed at $0.8317.
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.